These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 22074322)

  • 1. Inhibition of HCV 3a genotype entry through host CD81 and HCV E2 antibodies.
    Ashfaq UA; Qasim M; Yousaf MZ; Awan MT; Jahan S
    J Transl Med; 2011 Nov; 9():194. PubMed ID: 22074322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of infectious HCV pseudo typed particles and its utilization for studying the role of CD81 & SRBI receptors in HCV infection.
    Rafique S; Idrees M; Ali A; Sahibzada KI; Iqbal M
    Mol Biol Rep; 2014 Jun; 41(6):3813-9. PubMed ID: 24549717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on the role of neutralizing antibodies against envelope genes in resolving HCV pseudo-particles infection.
    Rafique S; Idrees M; Ali A; Iqbal M
    Mol Biol Rep; 2014 Jun; 41(6):3945-50. PubMed ID: 24566682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.
    Keck ZY; Li SH; Xia J; von Hahn T; Balfe P; McKeating JA; Witteveldt J; Patel AH; Alter H; Rice CM; Foung SK
    J Virol; 2009 Jun; 83(12):6149-60. PubMed ID: 19321602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2.
    Vasiliauskaite I; Owsianka A; England P; Khan AG; Cole S; Bankwitz D; Foung SKH; Pietschmann T; Marcotrigiano J; Rey FA; Patel AH; Krey T
    mBio; 2017 May; 8(3):. PubMed ID: 28512091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein.
    Owsianka AM; Tarr AW; Keck ZY; Li TK; Witteveldt J; Adair R; Foung SKH; Ball JK; Patel AH
    J Gen Virol; 2008 Mar; 89(Pt 3):653-659. PubMed ID: 18272755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission.
    Fofana I; Xiao F; Thumann C; Turek M; Zona L; Tawar RG; Grunert F; Thompson J; Zeisel MB; Baumert TF
    PLoS One; 2013; 8(5):e64221. PubMed ID: 23704981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Conserved E2 Residue W420 in Receptor Binding and Hepatitis C Virus Infection.
    Cowton VM; Angus AGN; Cole SJ; Markopoulou CK; Owsianka A; Dunlop JI; Gardner DE; Krey T; Patel AH
    J Virol; 2016 Aug; 90(16):7456-7468. PubMed ID: 27279607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of neutralizing monoclonal antibodies against Hepatitis C virus E2 protein effectively blocks virus infection.
    Bose M; Mullick R; Das S; Das S; Karande AA
    Virus Res; 2016 Sep; 224():46-57. PubMed ID: 27574733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential interaction strategies of hepatitis c virus genotypes during entry - An in silico investigation of envelope glycoprotein E2 - CD81 interaction.
    Bhattacharjee C; Nandy SK; Das P; Mukhopadhyay A
    Infect Genet Evol; 2019 Apr; 69():48-60. PubMed ID: 30639544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two conserved histidines (His490 and His621) on the E2 glycoprotein of hepatitis C virus are critical for CD81-mediated cell entry.
    Qin ZL; Ju HP; Gao TT; Wang WB; Ren H; Zhao P; Qi ZT
    J Gen Virol; 2015 Jun; 96(Pt 6):1389-1399. PubMed ID: 25701820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additional glycosylation within a specific hypervariable region of subtype 3a of hepatitis C virus protects against virus neutralization.
    Anjum S; Wahid A; Afzal MS; Albecka A; Alsaleh K; Ahmad T; Baumert TF; Wychowski C; Qadri I; Penin F; Dubuisson J
    J Infect Dis; 2013 Dec; 208(11):1888-97. PubMed ID: 23908491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimized cell systems for the investigation of hepatitis C virus E1E2 glycoproteins.
    Kalemera MD; Capella-Pujol J; Chumbe A; Underwood A; Bull RA; Schinkel J; Sliepen K; Grove J
    J Gen Virol; 2021 Jan; 102(1):. PubMed ID: 33147126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors.
    Lavie M; Sarrazin S; Montserret R; Descamps V; Baumert TF; Duverlie G; Séron K; Penin F; Dubuisson J
    J Virol; 2014 Sep; 88(18):10584-97. PubMed ID: 24990994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of a conserved RGE/RGD motif in HCV E2 in mediating entry.
    Rothwangl KB; Rong L
    Virol J; 2009 Jan; 6():12. PubMed ID: 19171049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor.
    Bartosch B; Vitelli A; Granier C; Goujon C; Dubuisson J; Pascale S; Scarselli E; Cortese R; Nicosia A; Cosset FL
    J Biol Chem; 2003 Oct; 278(43):41624-30. PubMed ID: 12913001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoprotein.
    Al Olaby RR; Cocquerel L; Zemla A; Saas L; Dubuisson J; Vielmetter J; Marcotrigiano J; Khan AG; Vences Catalan F; Perryman AL; Freundlich JS; Forli S; Levy S; Balhorn R; Azzazy HM
    PLoS One; 2014; 9(10):e111333. PubMed ID: 25357246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion.
    Haberstroh A; Schnober EK; Zeisel MB; Carolla P; Barth H; Blum HE; Cosset FL; Koutsoudakis G; Bartenschlager R; Union A; Depla E; Owsianka A; Patel AH; Schuster C; Stoll-Keller F; Doffoël M; Dreux M; Baumert TF
    Gastroenterology; 2008 Nov; 135(5):1719-1728.e1. PubMed ID: 18718838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions.
    Keck ZY; Xia J; Cai Z; Li TK; Owsianka AM; Patel AH; Luo G; Foung SK
    J Virol; 2007 Jan; 81(2):1043-7. PubMed ID: 17079294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissecting the role of putative CD81 binding regions of E2 in mediating HCV entry: putative CD81 binding region 1 is not involved in CD81 binding.
    Rothwangl KB; Manicassamy B; Uprichard SL; Rong L
    Virol J; 2008 Mar; 5():46. PubMed ID: 18355410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.